Intestinal epithelium integrity is crucial to maintain barrier function of the gastrointestinal tract. For numbers of digestive disorders, including inflammatory bowel diseases, the disruption of barrier integrity is a key event determining the outcomes of the disease^(^[@ref1]^,^[@ref2]^)^. To restore tissue homoeostasis following injury, a rapid activation of the wound-healing process is required. First, wound healing is initiated by epithelial restitution, during which cells surrounding the wound lose their polarity, undergo complex alterations of their adhesion properties, change their morphology and migrate toward the denuded area to cover the defect^(^[@ref3]^--^[@ref5]^)^. This is followed by cell proliferation, which is triggered to fill the wound with new enterocytes. Eventually, cell differentiation occurs to re-establish tissue architecture and function.

There is a wide variety of factors that can affect intestinal restitution and proliferation, including growth factors, such as transforming growth factor-beta (TGF-β) and epidermal growth factor (EGF), cytokines, regulatory peptides and SCFA^(^[@ref3]^,^[@ref6]^)^. Although many of these molecules have been studied and characterised extensively and their effect on intestinal epithelial cells have been described, little is known about the outcomes of their combination and the importance of their dosage. Interestingly, the content of colostrum, the first milk produced following birth, is rich in these compounds. In fact, in human subjects as well as in numerous animals, colostrum consumption after birth triggers a significant increase of intestinal size and changes in the tissue structure, positively affecting gastrointestinal functions^(^[@ref7]^)^. A decrease in Ig and growth factors is observed within the first milkings^(^[@ref8]^,^[@ref9]^)^, when colostrum production is replaced by milk.

Dairy calf management practices have evolved considerably over the past 100 years, leading to considerable increase of colostrum production, often exceeding the calf\'s needs^(^[@ref10]^,^[@ref11]^)^. Consequently, there is growing interest to exploit this dairy product for medical and nutritional applications. Since most of bioactive components present in colostrum and milk are found in the whey fraction following casein removal^(^[@ref12]^,^[@ref13]^)^, the use of colostrum whey to promote intestinal health of human subjects and animals has been proposed, but better understanding of mechanisms involved in its beneficial properties on intestinal epithelial cells is required.

In the present study, we investigated the effect of colostrum whey, a complex natural source of bioactive ingredients, on mechanisms involved in the wound-healing process using porcine IPEC-J2 and human Caco-2/15 cells. IPEC-J2 cells were selected for their great advantages compared with other intestinal epithelial cell lines, including the facts that they are non-transformed and they have the potential to differentiate and form polarised monolayers^(^[@ref14]^)^. Moreover, the swine model has been increasingly suggested over the past few years as a suitable model for human^(^[@ref15]^--^[@ref17]^)^. First, we verified the effect of colostrum whey and cheese whey on cell proliferation, adhesion, morphology and migration in IPEC-J2 and Caco-2/15 cells. The effect of colostrum whey was further investigated in IPEC-J2 cells, by evaluating gene expression profile following colostrum whey treatment using microarray analysis.

Materials and methods {#sec1}
=====================

Cell culture {#sec1-1}
------------

Non-transformed porcine intestinal epithelial IPEC-J2 cells, derived from newborn piglet jejunum^(^[@ref18]^)^, were a kind gift from Dr Joshua Gong (Agriculture and Agri-Food Canada, Guelph, Ontario, Canada). Cells were cultured in Dulbecco\'s modified Eagle\'s medium/Ham\'s F-12 \[1:1\] (Wisent) supplemented with 5 % heat-inactivated fetal bovine serum (FBS; Wisent), 1 % insulin--transferrin--selenium (premix; BD), 1 % glutamine and 5 ng/ml EGF (Wisent). For the induction of differentiation, confluent IPEC-J2 cells were grown in the FBS-deprived medium supplemented with 10^−7^ [m]{.smallcaps} dexamethasone (Sigma-Aldrich Canada) for 10 d. The Caco-2/15 human colon adenocarcinoma cell line^(^[@ref19]^)^ was cultured in Dulbecco\'s modified Eagle\'s medium high glucose (Invitrogen) supplemented with 10 % FBS, 25 m[m]{.smallcaps} HEPES and glutamax (Invitrogen).

Milk fractions {#sec1-2}
--------------

Bovine colostrum samples from the second and third milkings were collected from Holstein cows at the Laval University Animal Sciences Research Center (Deschambault, QC, Canada). As described by Montoni *et al.*^(^[@ref9]^)^, colostrum samples (total lacteal secretion) were collected within 24 h from fourteen Holstein cows aged 23--110 months (primapara or 2--7-calf multipara heifers). They were immediately frozen and kept at −18°C. These samples were used to prepare colostrum whey, as described previously^(^[@ref9]^)^. Briefly, colostrum samples were thawed, centrifuged at 10 000 ***g*** for 30 min at 4°C (Sorvall model RC-5B, GSA rotor, DuPont Instruments) and the solid fat layer was then carefully removed manually. The samples were then acidified to pH 4·6 with 1 [m]{.smallcaps}-HCl, and caseins were removed by centrifugation at 12 000 ***g*** for 15 min at 4°C. The crude whey was collected and the pH was adjusted to 7·0 with 1 [m]{.smallcaps}-NaOH. The colostrum whey samples were freeze-dried using a RePP model FFD-42-WS (The Virtis Co. Inc.). Fresh Mozzarella cheese whey obtained from a local cheese factory (L\'Ancêtre) was skimmed by using a pilot-scale milk separator (Alfa Laval). Bacterial contamination of cheese whey was reduced by microfiltration (TetraPak MSF1) through a 1·4 µm membrane (Membralox™). Microfiltered whey was concentrated by ultrafiltration (UF) through a 5 kDa membrane (Romicon, Koch Membrane Systems), freeze dried and stored at −20°C. Final protein concentrations for colostrum whey and cheese whey were 68·073 and 71·815 %, respectively. Both whey products were irradiated with a dose of 5 kGy using a Gammacell 220 irradiator unit (Atomic Energy of Canada Ltd) and refrozen at −20°C. For the experiments, milk fractions were diluted in OptiMEM (Invitrogen).

Proliferation assay {#sec1-3}
-------------------

IPEC-J2 and Caco-2/15 cells were seeded at a density of 10^4^ cells/well in a ninety-six-well plate and allowed to adhere to the plate overnight. Cells were further incubated for 24 h with increasing doses of milk fractions (0, 0·1, 1 and 10 mg/ml) in the serum-deprived culture medium. Cell proliferation was measured using the 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT; InVitrogen), which assess cell viability and proliferation as a function of redox potential. Briefly, fresh 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide stock solution (1 mg/ml in PBS) was prepared, and PMS (phenazine methosulfate 15 mg/ml in PBS, store in dark and −20°C) was diluted 1:100 in PBS. PMS was added to 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide solution (40:1), and 50 µl of the mix was added to each wells. Cells were incubated for 1 h before the absorbance was measured at 450/630 nm. The absorbance in untreated cells (0·0 mg/ml) was set as 100 %. In total, four independent experiments were done in triplicate.

Attachment studies {#sec1-4}
------------------

Immediately after trypsinisation, IPEC-J2 and Caco-2/15 cells were washed twice in the serum-free medium by centrifugation, and resuspended in their respective growing media supplemented with FBS, with or without colostrum whey (10 mg/ml) or cheese whey (10 mg/ml). Cells were seeded at the density of 10^5^/ml in 100-mm cell culture dishes. Attachment to the culture dish was measured after 18 h. For cell count, unattached cells were washed 3 times with PBS, detached using trypsin, resuspended in 10 ml of Dulbecco\'s modified Eagle\'s medium-5 % FBS and counted using a 'Countess™ Automated Cell Counter' (Invitrogen). Cells from three independent experiments were counted in triplicate.

Cell morphology {#sec1-5}
---------------

For cell morphology observations, IPEC-J2 and Caco-2/15 cells were resuspended in their respective growing media supplemented with FBS, with increasing concentrations (0·0, 0·1, 1 and 10 mg/ml) of colostrum or cheese wheys. Cells were seeded at the density of 10^5^/ml in 100-mm cell culture dishes. Morphology was observed after 48 h. Cells were viewed with the Primo Vert microscope and photographed using the digital image processing software Axiovision 4.8 (Zeiss, Toronto, Ontario, Canada). Images are representative of three independent experiments.

Wound-healing assay {#sec1-6}
-------------------

IPEC-J2 cells were seeded at the density of 10^5^ cells/ml in 100-mm cell culture dishes. After reaching confluence, cells were allowed to differentiate for 10 d. In every culture dishes, three scratches of 10 mm were made on cell monolayers with a sterile razor blade. Detached cells were rinsed off three times with the serum-free Dulbecco\'s modified Eagle\'s medium. Milk fractions (10 mg/ml) were added to cells in the culture medium deprived of FBS, insulin--transferrin--selenium and EGF. Cells were photographed before and 18 h after wounding, using a Primo Vert microscope (Zeiss). Cell migration was quantified with the digital image-processing software Axiovision 4.8 (Zeiss) by measuring the surface covered by migrating cells, starting at the edge of each scratch. Images are representative of three independent experiments.

Microarray analysis {#sec1-7}
-------------------

Total RNAs from differentiated IPEC-J2 cells treated without (control) or with colostrum whey (10 mg/ml) for 2 h were extracted using Qiagen RNeasy kit (Qiagen). RNA sample quality was determined with the Agilent 2100 Bioanalyzer (Agilent Technology), using the RNA 6000 Nano Kit. RIN measured were higher than 9 for all samples. cDNA synthesis was performed with 25 ng of RNA and hybridisation with a Agilent Porcine Gene Expression Microarray (catalogue \#G2519F-026440) at the Microarray platform of the McGill University and Genome Quebec Innovation Centre. The microarray contains 43 603 probes, with a third of these probes representing well characterised genes. Three independent experiments were done for each condition. Data analysis, normalisation, average difference and expression for each feature on the microarray were done using the Flexarray software version 1.6.1.

Functional classification {#sec1-8}
-------------------------

Genes with expression levels increased or decreased more than 2-fold (−1 \> fold change (log2) \>1, *P* \< 0·05) were selected and analysed according to their Gene Ontology classification, using Toppgene Suite (Transcriptome, ontology, phenotype, proteome and pharmacome annotations based gene list, <http://toppgene.cchmc.org/>). To identify biological processes significantly affected in colostrum-treated cells, Bonferroni correction was used with a *P*-value cut-off set at 0·05.

Quantitative PCR analysis {#sec1-9}
-------------------------

Differentiated IPEC-J2 cells were treated with colostrum whey (10 mg/ml) or left untreated for 2 h. RNAs were prepared with Qiagen RNeasy kit (Qiagen). cDNAs were synthesised using oligo(dT) and Superscript II reverse transcriptase (Invitrogen), following the manufacturer\'s protocol. Quantitative PCR (qPCR) was performed by using Power SYBR Green PCR Master Mix and the 7500 fast real-time PCR system (Applied Biosystems, Life Technologies Inc). Primers designed with Primer-Blast (<http://www.ncbi.nlm.nih.gov/tools/primer-blast>) are listed in [Table 1](#tab01){ref-type="table"}. All data were analysed with the ∆∆CT method, using β-actin and PPIA as internal controls. Table 1.List of primers for quantitative PCR analysis of colostrum-regulated gene targets identified by microarray analysisGene symbolRefSeqAccessionPrimerSequence (5′-- \> 3′)StartStopAREGNM_214376ForwardCACAGCTCCGCGGGACCAAT172191ReverseCCGTTGACGTCCAGTCCAGCA281261CDKN2BNM_214124ForwardGCAAGTGGAGACCGTGCGTCA82102ReverseCACGTGCGCTGCCCATCATCA188168CXCR4NM_213773ForwardAAGGATGGACGCGCCACACA2342ReverseGCATCCGAGAAGCGTGCCCC123104F3NM_213785ForwardAAGTCGCATTGAGTGCACCAGCC818840ReverseACACAGGCGGGACGAGGACG927908HAS3NM_001001268ForwardGCCGGCTTCTTTGTGTGGCG436455ReverseTGCTGGCCCGCACCACATTC544525HBEGFNM_214299ForwardCGTCGGTGGTGCTGAAGCTCT1434ReverseATTGCTGGTTCCATCCGCCAGC11796IL-8NM_213867ForwardCAGCCCGTGTCAACATGACTTCCA7093ReverseGCACTGGCATCGAAGTTCTGCAC191169NGFXM_001929549ForwardCGAGAGGGAGAGGGTGGCTGG1838ReverseAACGCCCACCTGCTTGTTGC11798PLAUNM_213945ForwardGGTGAGAGTCACCGGCCTGC570589ReverseTAAAGCGGGGCCTCAGAGCCT669649PTGS1XM_001926129ForwardGCACCGGTGAACCCCTGTTGT126146ReverseCAGAGTAGCCCGTGCGGGTG231212SERPINE1NM_213910ForwardCCACCCCCGACGGCCATTAC847866ReverseTGGTGAGGGCGGAGAGAGGC960941SMAD7NM_001244175ForwardGATGCTGTGCCTTCCTCCGCT676696ReverseGTGACCGATCCCCAGGCTCCA775755TAGAPNM_001243543ForwardCGGCACATTCCAGCGTTGCC10141033ReverseACGTCGGGGTCGGGATCGTT11251106β-actinXM_003357928ForwardCTCTTCCAGCCCTCCTTCCT447466ReverseGCGTAGAGGTCCTTCCTGATGT518497PPIANM_214353ForwardTGCAGACAAAGTTCCAAAGACAG7597ReverseGCCACCAGTGCCATTATGG225207

Statistical methods {#sec1-10}
-------------------

Comparisons of quantitative data were analysed by a one-way ANOVA. When a significant difference was identified by ANOVA (*P* \< 0·05), Dunnett\'s adjustment (*post hoc*) was used to identify differences between treatments and the control untreated cells (*P* \< 0·05). Analysis was performed using the SigmaPlot software (version 12.5). All data were found to comply with ANOVA assumptions. For microarray and qPCR results, fold change between colostrum whey-treated groups and untreated control groups were analysed in log2 scale, and comparisons of data were done using Welch\'s *t*-tests. Data are considered significant when *P* \< 0·05. Data are reported as means with their standard errors.

Results {#sec2}
=======

The impact of colostrum whey on biological processes involved in wound healing were evaluated in intestinal epithelial cells and compared with effects mediated by cheese whey. First 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide assay was performed in both porcine IPEC-J2 and human Caco-2/15 cells in order to determine the effect of wheys on cell proliferation, and different concentrations were tested to identify the dose to use in further experiments. Results showed that both colostrum and cheese wheys increased cell proliferation, with the highest values observed with the highest concentration tested (10 mg/ml; [Fig. 1](#fig01){ref-type="fig"}). Therefore, the highest dose was selected for each whey to test cell attachment, cell migration and to measure gene expression. Fig. 1.Colostrum and cheese whey treatments increased cell proliferation in intestinal epithelial cells. (a) IPEC-J2 and (b) Caco-2/15 cells were incubated with different concentrations of colostrum whey or cheese whey for 24 h. Cell proliferation was measured with an 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay. Values are the mean percentage of proliferating cells compared with control cells (0 mg/ml), as determined by the XTT test, with means with their standard errors of four independent experiments done in triplicate. Mean values were significantly different from control by the *post hoc* analysis. \*\**P* \< 0·01; \**P* \< 0·05.

Cell adhesion process was evaluated by measuring IPEC-J2 and Caco-2 cells attachment to the culture dish. The quantification of attached cells revealed that neither colostrum whey nor cheese whey affected cell capacity to attach to the culture dish in IPEC-J2 cells, while colostrum whey treatment significantly decreased (*P* \< 0·01) the attachment of Caco-2/15 cells ([Fig. 2(B)](#fig02){ref-type="fig"}). Fig. 2.Cell attachment is affected specifically in Caco-2/15 cells treated with colostrum whey. (a) IPEC-J2 and (b) Caco-2/15 cells were recovered after trypsinisation and resuspended in the FBS-supplemented medium, with or without colostrum whey (10 mg/ml) or cheese whey (10 mg/ml). Cells were seeded and allowed to attach to the cell culture dish for 18 h, followed by cell count. Values are the mean of viable cells/ml, with means with their standard errors of three independent experiments. Mean values were significantly different from control by the *post hoc* analysis. \*\**P* \< 0·01.

Interestingly, morphological changes were noticed in IPEC-J2 cells following the attachment assay. These morphological changes were further investigated by allowing cells to attach to the culture dish for 48 h following resuspension, with or without decreasing concentrations of colostrum or cheese wheys. While important morphological changes were confirmed in newly attached IPEC-J2 cells following cheese whey treatment, changes were less significant in colostrum whey-treated cells ([Fig. 3](#fig03){ref-type="fig"}). Cells were stretched out with branched cytoplasm, and were more disjointed than control cells. Morphological changes subsided with lower concentrations of wheys. In Caco-2/15 cells, no morphological changes were observed, while a decrease of attached cells was noticeable in colostrum whey (10 mg/ml)-treated cells, confirming results obtained with the attachment assay. Fig. 3.Morphological changes are observed in newly attached IPEC-J2 cell treated with colostrum and cheese wheys. (a) IPEC-J2 and (b) Caco-2/15 cells were recovered after trypsinisation and resuspended in Dulbecco\'s modified Eagle\'s medium supplemented with increasing concentrations (0·0, 0·1, 1 and 10 mg/ml) of colostrum or cheese wheys. Cells were seeded in cell culture dishes, and morphology was observed by microscopy after 48 h of incubation. Images shown are representative of three independent experiments.

Finally, effect of colostrum and cheese wheys on cell migration was assessed by wound healing assay using non-proliferative differentiated IPEC-J2 cells. Results showed a significant increase in IPEC-J2 cell migration in colostrum whey-treated cells compared with untreated cells, while cheese whey had no impact on cell migration ([Fig. 4](#fig04){ref-type="fig"}). No migration was observed in differentiated Caco-2/15 cells (data not shown). Fig. 4.Colostrum whey promotes IPEC-J2 cell migration. IPEC-J2 monolayers were wounded with a razor blade, before treatment with colostrum whey or cheese whey (10 mg/ml). Migration was (a) measured and (b) photographed after 18 h. The graph represents mean values from three independent experiments with their standard errors. Mean values were significantly different from control by *post hoc* analysis. \*\**P* \< 0·01.

To further establish the mechanisms involved in the regulation of cellular processes by colostrum whey, a gene expression profile of colostrum-treated and -untreated IPEC-J2 cells was obtained by microarray analysis. Genes that showed significant 2-fold increase or decrease expression (−1\> log2-fold change \>1; *P* \< 0·05) were selected. In total, 102 probes were significantly increased or decreased more than 2-fold in colostrum whey-treated cells, in which twenty-nine known and characterised genes were identified. These genes are listed in [Table 2](#tab02){ref-type="table"}. Also, thirteen genes were selected from the microarray results (eleven genes involved in proliferation, migration, or adhesion, as well as two genes involved in other biological processes), and their expression in IPEC-J2 cells treated with colostrum whey was verified by qPCR. Results obtained with qPCR are shown in the right panel of [Table 2](#tab02){ref-type="table"}, and confirmed the increase of CDKN2B, NGF, SMAD7 and TAGAP (log2-fold change \>1), as well as the increase of AREG, CXCR4, F3, HAS3, IL-8 and PLAU (log2-fold change \>0·5). Table 2.List of known genes significantly increased or decreased more than 2-fold in colostrum whey-treated IPEC-J2 cells, as determined by microarray analysis and quantitative PCR analysisFold change (log2)Gene symbolGene namePrimary accessionProbe nameMicroarrayq-PCRAREGAmphiregulinNM_214376A_72_P4401211·18\*0·75†A_72_P3027991\*CDKN2BCyclin-dependent kinase inhibitor 2BNM_214124A_72_P0776161·44\*1·49\*CITED2Cbp/p300-interacting transactivator 2-likeXM_001925774A_72_P491235−1·27\*A_72_P555835−1·07A_72_P548306−1·07\*A_72_P192006−1·17\*A_72_P500550−1·23\*CSF2Colony-stimulating factor 2NM_214118A_72_P0777262·12\*CXCR4Chemokine (C--X--C motif) receptor 4AK238923A_72_P6618571·02\*0·98†CYP1A1Cytochrome P450 1A1NM_214412A_72_P4438041·73\*A_72_P2233621·6\*CYR61Cysteine-rich, angiogenic inducer, 61ENSSSCT00000007604A_72_P5808521·28\*A_72_P6882811·23\*A_72_P5520211·1\*A_72_P3193031\*F3Tissue factorNM_213785A_72_P1774611·45\*0·71\*A_72_P6418351·37\*FOSFBJ murine osteosarcoma viral oncogene homologueNM_001123113A_72_P4412841·12\*A_72_P6701451·11\*A_72_P2053071·04\*GADD45AGrowth arrest and DNA-damage-inducible, alphaNM_001044599A_72_P1469861·41\*GADD45GGrowth arrest and DNA-damage-inducible, gammaENSSSCT00000010506A_72_P0112761·05\*HAS3Hyaluronan synthase 3NM_001001268A_72_P3032841·36\*0·86\*HBEGFHeparin-binding EGF-like growth factorNM_214299A_72_P0357561·27\*1·44A_72_P1787511·06\*HRHairless proteinTC543384A_72_P3559532·59\*IL-8IL-8NM_213867A_72_P2323671·04\*0·69†NGFBeta-nerve growth factor-likeENSSSCT00000007392A_72_P2908091·54\*1·30\*PLAUPlasminogen activator, urokinaseNM_213945A_72_P0102461·46\*0·97\*A_72_P0731011·02\*PTGS1Prostaglandin-endoperoxide synthase 1AK232305A_72_P0635911·04\*0·80RNF39RING finger protein 39-likeXM_003128244A_72_P1080961·89\*SERPINE1Serpin peptidase inhibitor, clade E, member 1NM_213910A_72_P0773511·33\*0·75A_72_P5855961·14\*A_72_P6684991·12\*SLITRK6SLIT and NTRK-like family, member 6ENSSSCT00000010401A_72_P452998−1·01\*SMAD7SMAD family member 7ENSSSCT00000004979A_72_P4923691·35\*3·16\*SOX9SRY (sex-determining region Y)-box 9NM_213843A_72_P1469311·08\*SPB9Serine protease inhibitor 9TC587447A_72_P3349031·3\*TAGAPt-cell activation Rho GTPase-activating proteinENSSSCT00000004481A_72_P7098051·75\*1·24\*TIPARPTCDD-inducible poly(ADP-ribose) polymeraseAK343870A_72_P0240511·37\*A_72_P0367111·18\*WNT11Wingless-type MMTV integration site family, 11ENSSSCT00000016217A_72_P2199171·37\*XKR8XK-related protein 8-likeXM_003127736A_72_P2596371·24\*ZNF503Zinc finger protein 503-likeXM_003133082A_72_P161271−1·11\*[^1]

To classify up-regulated and down-regulated genes according to their biological processes, ToppGene suite database for functional enrichment based on Ontologies (Gene Ontology, Pathway) was used. This analysis revealed that, indeed, biological processes involved in wound healing were significantly affected in colostrum whey-treated cells. Genes associated with proliferation (thirteen up-regulated genes), adhesion (six up-regulated and one down-regulated genes) and migration (ten up-regulated and one down-regulated genes) were identified. These genes are shown in the volcano plot representing gene expression in colostrum whey-treated cells ([Fig. 5](#fig05){ref-type="fig"}). Classification of each up-regulated or down-regulated genes according to biological processes is also presented ([Table 3](#tab03){ref-type="table"}). Fig. 5.Colostrum whey treatment significantly increased or decreased gene expression involved in proliferation, adhesion or migration of IPEC-J2. Gene expression in IPEC-J2 cells treated with colostrum whey (10 mg/ml) for 2 h, as determined by microarray analysis, is illustrated in the volcano plot. Genes involved in proliferation, adhesion or cell migration are represented in diamond-shape. Table 3.Functional classification (Gene Ontology (GO) biological processes) of genes with increased or decreased expression in colostrum whey-treated IPEC-J2 cells.Gene symbolGene nameRegulation of cell migration (GO:0030334), \**P* = 1 011 × 10^−7^Regulation of cell adhesion (GO:0030155), \**P* = 3·360 × 10^−5^Regulation of cell proliferation (GO:0042127), \**P* = 4 707 × 10^−4^Response to wounding (GO:0009611), \**P* = 8·904 × 10^−3^AREGAmphiregulinXCDKN2BCyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)XCITED2Cbp/p300-interacting transactivator 2-likeXXCSF2Colony- stimulating factor 2 (granulocyte--macrophage)XCXCR4Chemokine (C--X--C motif) receptor 4XXCYP1A1Cytochrome P450 1A1XCYR61Cysteine-rich, angiogenic inducer, 61XXXXF3Tissue factorXXXFOSFBJ murine osteosarcoma viral oncogene homologXGADD45AGrowth arrest and DNA-damage-inducible, alphaGADD45GGrowth arrest and DNA-damage-inducible, gammaHAS3Hyaluronan synthase 3HBEGFHeparin-binding EGF-like growth factorXXXHRHairless proteinIL-8IL-8XXXXNGFBeta-nerve growth factor-likeXXPLAUPlasminogen activator, urokinaseXXXXPTGS1Prostaglandin-endoperoxide synthase 1XRNF39RING finger protein 39-likeSERPINE1Serpin peptidase inhibitor, clade E member 1XXXXSLITRK6SLIT and NTRK-like family, member 6SMAD7SMAD family member 7XXSOX9SRY (sex determining region Y)-box 9XXXSPB9Serine protease inhibitor 9TAGAPt-cell activation Rho GTPase-activating protein-likeTIPARPTCDD-inducible poly(ADP-ribose) polymeraseWNT11Wingless-type MMTV integration site family, member 11XXXKR8XK-related protein 8-likeZNF503Zinc finger protein 503-like[^2]

Discussion {#sec3}
==========

The aim of the present study was to survey the potential of colostrum whey to promote intestinal health and to propose cellular mechanisms responsible for these beneficial properties. Therefore, the effects of colostrum whey on biological processes involved in intestinal homoeostasis were compared with the ones observed with cheese whey, a defatted and decaseinated by-product obtained during cheese making. The highest amount of wheys added to cells (10 mg/ml or 1 %) was calculated to match estimated amount of product believed to reach intestinal epithelial cells following ingestion.

We have shown that important biological processes involved in wound healing, including proliferation and migration, were increased by colostrum whey in intestinal epithelial cells. Interestingly, cheese whey failed to induce cell migration, which is a major step in epithelial restitution. These results clearly demonstrated that, although the two products compared in this work had similar ingredients and protein content, fundamental differences between colostrum whey and cheese whey composition could trigger different outcomes on intestinal epithelial cells.

Indeed, amounts of growth factors are generally higher in colostrum compared with milk from late lactation^(^[@ref8]^,^[@ref9]^)^. Since growth factors play important roles in wound healing processes^(^[@ref20]^)^, it is likely that the various growth factors found in colostrum whey are involved in the effects we observed. However, a previous study performed with milk obtained from different stages of lactation also measured variation in growth-promoting activity of human fetal small intestinal cells, and concluded that the concentration level of TGF-β and IGF-I in milk could not fully explain these differences^(^[@ref21]^)^. Also, evidences have shown that milk is significantly superior than EGF, IGF-1, fibroblast growth factor, human growth factor and TGF-α, individually or in combination, to promote growth activity in human intestinal epithelial cells^(^[@ref22]^)^. Lactoferrin, found in colostrum whey, is also known for its beneficial effect on wound healing^(^[@ref23]^)^, yet results obtained in our laboratory showed that lactoferrin is unable to increase cell migration in IPEC-J2 cells (data not shown). Therefore, growth and wound healing--promoting activity of colostrum are complex and most likely multifactorial. Eventually, compositional data on colostrum whey could enable us to further elaborate on the role of each component.

Significant morphological changes were observed when resuspended IPEC-J2 cells were treated with cheese whey before being allowed to attach to culture dish, while changes observed in colostrum whey-treated cells were hardly perceptible. Interestingly, these morphological changes were only observed when cheese or colostrum whey were added to resuspended IPEC-J2 cells, thus unpolarised cells, but no morphological changes were observed when whey products were added to cells already attached to the cell culture dish (data not shown). In Caco-2/15 cells, no morphological change was observed, but a decrease in cell attachment to the culture dish was noticed in colostrum whey-treated cells. While no further investigation was done to determine the cause of the morphological changes observed in IPEC-J2 cells, we believe the induction of an epithelial--mesenchymal transition (EMT) might be involved. In EMT, polarised epithelial cells undergo biochemical changes leading to the acquisition of mesenchymal cell characteristics. These changes include loss of cell adhesion, cell--cell junction dissolution, actin reorganisation, loss of cell polarity, E-cadherin as well as Zona occludens proteins repression and metalloprotease induction^(^[@ref24]^)^. EMT is essential for many biological processes such as wound healing, tissue regeneration and organ fibrosis, but is also associated with initiation of metastasis for cancer progression. It is likely that growth factors present in colostrum and milk, including TGF-β and EGF, as well as their precise proportion play major roles in the induction of these morphological changes, since they are well known for their capacity to promote EMT^(^[@ref25]^--^[@ref28]^)^. Indeed, studies have shown that combination of TGF-β1 with EGF-induced cell migration, invasion and anchorage-independent growth^(^[@ref29]^,^[@ref30]^)^. In fact, in these studies, dramatic morphological changes characteristic of EMT are observed after combination of EGF and TGF-β1 treatment, similarly to the results we obtained following cheese whey treatment.

Finally, results obtained from the microarray analysis revealed that the expression of a significant number of genes involved in biological processes affecting gastrointestinal health was increased or decreased by colostrum whey. Therefore, this suggests that colostrum whey promotes processes involved in wound healing by regulating the expression of a specific set of genes in intestinal epithelial cells. Taken together, our results point out at a distinctive health potential of colostrum-based ingredients, and the next phase should focus on their characterisation.

Conclusion {#sec3-1}
----------

In conclusion, we show that a gene expression programme induced by colostrum whey promotes growth and wound healing properties of intestinal epithelial cells. Divergent results obtained following cheese whey treatment indicates that a delicate balance between growth factors and other bioactive components may be crucial for the regulation of intestinal epithelial cell homeostasis. Therefore the unique functionality of colostrum whey in intestinal epithelial cells should be taken into account and investigated further to develop its potential as food additive.
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[^1]: Fold changes = log2 (colostrum whey/control). \**P* \< 0·05, †*P* \< 0·1.

[^2]: *\*P* values for the Bonferroni test.
